

Marc Ychou

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1138857/marc-ychou-publications-by-citations.pdf>

Version: 2023-09-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

8,557
citations

14
h-index

33
g-index

33
ext. papers

10,367
ext. citations

10
avg, IF

4.9
L-index

#	Paper	IF	Citations
30	FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. <i>New England Journal of Medicine</i> , 2011 , 364, 1817-25	59.2	4650
29	Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1715-21	2.2	1271
28	FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2395-2406	59.2	1047
27	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. <i>Nature Medicine</i> , 2014 , 20, 430-5	50.5	474
26	Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. <i>European Journal of Cancer</i> , 2006 , 42, 2212-21	7.5	404
25	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , 2015 , 16, 937-48	21.7	240
24	Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. <i>European Journal of Cancer</i> , 2013 , 49, 3149-58	7.5	102
23	A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. <i>Annals of Surgical Oncology</i> , 2013 , 20, 4289-97	3.1	66
22	Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. <i>Oncologist</i> , 2011 , 16, 1557-64	5.7	64
21	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019 , 24, 185-192	5.7	52
20	Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial. <i>Cells</i> , 2019 , 8,	7.9	40
19	Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. <i>Clinical Chemistry</i> , 2018 , 64, 317-328	5.5	28
18	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , 2018 , 67, 1095-1102	19.2	16
17	A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2016 , 11, 293-308	5	14
16	FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study Prodige 14 [ACCORD 21 (METHEP-2), a unicancer GI trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3512-3512	2.2	13
15	Modulating PKC β Activity to Target Wnt/ β Catenin Signaling in Colon Cancer. <i>Cancers</i> , 2019 , 11,	6.6	11
14	Preoperative intraperitoneal oxaliplatin for unresectable peritoneal carcinomatosis of colorectal origin: a pilot study. <i>Pleura and Peritoneum</i> , 2016 , 1, 209-215	2	10

13	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , 2020 , 130, 63-71	7.5	7
12	Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017 , 22, 141-149	1.5	7
11	Neoadjuvant therapy for gastroesophageal adenocarcinoma. <i>World Journal of Clinical Oncology</i> , 2016 , 7, 284-92	2.5	7
10	Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019 , 123, 101-111	7.5	6
9	The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. <i>EBioMedicine</i> , 2020 , 51, 102574	8.8	6
8	Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1). <i>International Journal of Cancer</i> , 2021 , 148, 682-691	7.5	5
7	Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. <i>Surgery</i> , 2019 , 165, 703-711	3.6	4
6	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020 , 19, 301-310.e1	3.8	3
5	FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. <i>BMC Cancer</i> , 2021 , 21, 564	4.8	3
4	Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.. <i>Frontiers in Oncology</i> , 2022 , 12, 842402	5.3	3
3	Reproductive Decision-Making in MMR Mutation Carriers After Results Disclosure: Impact of Psychological Status in Childbearing Options. <i>Journal of Genetic Counseling</i> , 2016 , 25, 432-42	2.5	2
2	Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy. <i>Digestive and Liver Disease</i> , 2019 , 51, 1185-1191	3.3	1
1	Image-Guided Liver Stereotactic Body Radiotherapy Using VMAT and Real-Time Adaptive Tumor Gating: Evaluation of the Efficacy and Toxicity for Hepatocellular Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	1